NeuroEndocrine Cancer Australia (NECA) CEO, Meredith Cummins attended the annual CommNETs (Commonwealth countries – Canada, Australia and New Zealand) Research Workshop held on 30 November to 2 December 2022 in Hawaii.
There were over 30 attendees which included NET multidisciplinary healthcare professionals and Patient Organisations and NECA was thrilled to be part of this meeting.
Many Clinical Trials were discussed, and expressions of interest were made to conduct some of the trials across the 3 countries.
NECA , whilst there, was invited to participate in a CommNETs/NANETS Guidelines Panel over 2 days which will develop guidance documents. Areas which will be researched in literature reviews will be including, however not limited to –
- Clinical : Tumour grade, Patient age/Presenting Symptoms/comorbidities, Primary site, molecular profile (MGMT loss, MEN1, DAXX, ATRX, p53, RB, transcriptional subtypes), MSI
- Functional imaging – Dotatate PET, Octreoscan, FDG PET, dual PET, NETPET score
- Functional markers (e.g. 24h u5HIAA, serum/platelet serotonin, gastrin/VIP, insulin, glucagon), CgA, pancrestatin, NETest
From the literature review the document will be reviewed including NET Consumer reviews from each country. The group members were diverse and many differences were acknowledged with regards to health systems and availability / non-availability of investigations, and management of NETs.
“It was such an honour to be invited and NECA is looking forward to the ongoing of these documents and eventually publication” said NECA CEO, Meredith Cummins.
“Group collaboration is the heart of CommNETs, and so much was accomplished this year. It was wonderful to be able to meet face to face and form such strong bonds and networks”.
Plans are in place to hold CommNETs in New Zealand next year following on from AGITG.
